Table 1 The various mouse models of liver cancer.
From: Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Genes | Tumor type | Mouse strains | Latency | Reference |
|---|---|---|---|---|
Genetically engineered mouse models for liver cancer | ||||
AAT | HCC | Transgenic mice using human alpha 1-antitrypsin M and Z genomic clones | 52–90 weeks | Geller et al.60 |
NEMO−/− | HCC | NEMOΔhepa mice | 52 weeks | Beraza et al.61 |
PTEN−/− | HCC | PTEN-deficient mice | 42–44 weeks | Watanabe et al.62 |
PTEN−/− + GRP94−/− | cHCC-ICC | PTEN and GRP94 two liver-specific knockout mouse | 25 weeks | Chen et al.63 |
HCV core | HCC | Transgenic for the HCV core gene | 80–105 weeks | Moriya et al.64 |
TAK1−/− | HCC | Tak1Δhepa mice | 39 weeks | Inokuchi et al.65 |
HBx | HCC | Transgenic mice expressed HBV-encoded gene products | 52–104 weeks | Chisari et al.66 |
KRASG12D + HBx | HCC | Kras(G12D) and HBx double transgenic mice | 34 weeks | Ye et al.67 |
c-myc | HB | c-myc single transgenic mice | 65–90 weeks | Thorgeirsson et al.68 |
c-myc + EGF | HCC | Autocrine growth factor IgEGF and c-myc single transgenic mice | 12–18 weeks | Tönjes et al.69 |
c-myc + E2F1 | HCC | c-Myc/E2F1 transgenic mouse | 26–39 weeks | Calvisi et al.70 |
P53−/− + c-myc | HCC | c-Myc/p53KO mice | 21 weeks | Klocke et al.71 |
P53−/− | HCC | P53Δhepa mice | 60 weeks | Katz et al.72 |
EGF | HCC | Autocrine growth factor IgEGF transgenic mice | 24–36 weeks | Tönjes et al.69 |
SV40 T-antigen | HCC | Mice expressing SV 40 early sequences | 20 weeks | Lou et al.73 |
E2F-1 | HCC | E2f1 transgenic mice | 52 weeks | Lee et al.74 |
APC−/− | HCC | APCΔhepa mice | 38 weeks | Colnot et al.75 |
TGF- a | HCC | TGF-alpha transgenic mice | >52 weeks | Lee et al.76 |
β-catenin(Dex3) + HRASG12V | HCC | Mouse strain containing a mutant beta-catenin allele of which exon 3 was sandwiched by loxP sequences [Catnb(lox(ex3))] | 8 weeks | Harada et al.77 |
Application of the hydrodynamic transfection methodology to induce liver cancer | ||||
myr-AKT | HCC | C57BL/6J, FVB/N | 6 months | Calvisi et al.78 |
myr-AKT and DN90-b-catenin | HCC | C57BL/6J, FVB/N | 1 months | Calvisi DF et al.79 |
myr-AKT and NRasV12 | cHCC-ICC | C57BL/6J, FVB/N | 1 months | Ho et al.54 |
myr-AKT and NICD | ICC | C57BL/6J, FVB/N | 3 weeks | Fan et al.6 |
c-Met and DN90-b-catenin | HCC | C57BL/6J, FVB/N | 3 months | Tward et al.80 |
NRasV12 and DN90-b-catenin | HCC | C57BL/6J, FVB/N | 3 months | Lee et al.81 |
NEMO (IKKγ) KO + c-Myc | cHCC-ICC | C57BL/6J, FVB/N | 45 days | He et al.49 |
Myc and human NRASG12V | HCC | p19Arf−/− | 4 weeks | Seehawer et al.33 |
mouse Myc and Akt1 | HCC | p19Arf−/− | 4 weeks | Seehawer et al.33 |
FAK and DN90-b-catenin | HCC | 57BL/6J, FVB/N | 24 weeks | Shang et al.82 |
myr-AKT and c-Myc | HCC | 57BL/6J, FVB/N | 8 weeks | Yamamoto et al.4 |
myr-AKT/c-Myc/YAP | HCC | 57BL/6J, FVB/N | 3 weeks | Yamamoto et al.4 |
myr-AKT and YAP | ICC | 57BL/6J, FVB/N | 6 weeks | Yamamoto et al.4 |
c-Myc and YAP | HB | 57BL/6J, FVB/N | 16 weeks | Yamamoto et al.4 |
NICD1 | ICC | 57BL/6J, FVB/N | 5 months | Fan et al.6 |
HRasV12 and shP53 | Undifferentiated liver tumors | 57BL/6J, FVB/N | 1 week | Ju et al.83 |
NRasV12 | cHCC-ICC | Ink4A/Arf−/− | 7 weeks | Carlson et al.55 |
myr-AKT and Spry2Y55F | HCC | 57BL/6J, FVB/N | 4 months | Wang et al.84 |
c-Myc and shp53 | HCC | 57BL/6J, FVB/N | 7 months | Ju et al.85 |
AKT/Fbxw7ΔF | ICC | 57BL/6J, FVB/N | 10 weeks | Wang et al.23 |
Nras-FAH and shP53 | HCC | Fah−/− | 10 weeks | Wangensteen et al.86 |
Bmi1 and NRasV12 | HCC | 57BL/6J, FVB/N | 6 months | Xu et al.87 |
Application of the chemical carcinogens to induce liver cancer | ||||
Diethylnitrosamine (DEN) | HCC | 57BL/6J, FVB/N | 14 months | Ngo et al.57 |
Aristolochic acid | HCC, cHCC-ICC | 57BL/6J, FVB/N | In a dose-dependent manner | Lu et al.58 |
